{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T22:01:05Z","timestamp":1783720865897,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This study was conducted to identify factors associated with the safety and effectiveness of pembrolizumab in Japanese patients with unresectable urothelial carcinoma and to confirm the real-world safety and effectiveness of pembrolizumab in Japanese patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This multicenter, observational, post-marketing surveillance was conducted over a 1-year observation period starting at pembrolizumab initiation (200-mg pembrolizumab every 3\u00a0weeks); data were collected from case report forms (3\u00a0months and 1\u00a0year). Safety measures included treatment-related adverse events and adverse events of special interest (AEOSI). Effectiveness assessments included tumor response, objective response rate (ORR), and disease control rate (DCR).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 1293 patients were evaluated for safety and 1136 for effectiveness. At 12\u00a0months, the treatment-related adverse event incidence was 53.8% (<jats:italic>n<\/jats:italic>\u2009=\u2009696) and that of AEOSI was 25.0% (<jats:italic>n<\/jats:italic>\u2009=\u2009323). The most frequent AEOSI of any grade were endocrinological disorder (10.4%, <jats:italic>n<\/jats:italic>\u2009=\u2009134), interstitial lung disease (ILD) (7.2%, <jats:italic>n<\/jats:italic>\u2009=\u200993), and hepatic function disorder (4.9%, <jats:italic>n<\/jats:italic>\u2009=\u200964). Multivariate analysis demonstrated that the risk of developing ILD was almost seven times greater (odds ratio 6.60) in patients with a comorbidity of ILD, and approximately twice as high in patients aged\u2009\u2265\u200965\u00a0years (odds ratio 2.24) and with smoking history (odds ratio 1.79). The ORR was 26.1% and the DCR was 50.7%. The ORR was 46.4% in patients with a Bellmunt risk score of 0 and decreased as the Bellmunt risk score increased.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This post-marketing surveillance confirmed the safety and effectiveness of pembrolizumab in Japanese patients with unresectable urothelial carcinoma in the real-world setting.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-023-10930-2","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T09:02:38Z","timestamp":1687251758000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance"],"prefix":"10.1186","volume":"23","author":[{"given":"Hiroyuki","family":"Nishiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Minegishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiroh","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,20]]},"reference":[{"key":"10930_CR1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ajur.2016.09.005","volume":"3","author":"T Kobayashi","year":"2016","unstructured":"Kobayashi T. Understanding the biology of urothelial cancer metastasis. Asian J Urol. 2016;3:211\u201322.","journal-title":"Asian J Urol"},{"key":"10930_CR2","unstructured":"International Agency for Research on Cancer. WHO. Bladder: Globocan 2020. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/30-Bladder-fact-sheet.pdf. Accessed 21 Apr 2022."},{"key":"10930_CR3","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/jjco\/hyx017","volume":"47","author":"T Matsuda","year":"2017","unstructured":"Matsuda T, Okuyama A. Incidence rate for bladder cancer in Japanese in Japan and in the United States from the Cancer Incidence in Five Continents. Jpn J Clin Oncol. 2017;47:284\u20135.","journal-title":"Jpn J Clin Oncol"},{"key":"10930_CR4","unstructured":"National Cancer Center. Cancer Statistics in Japan 2022. https:\/\/ganjoho.jp\/public\/qa_links\/report\/statistics\/2022_en.html. Accessed 21 Apr 2022."},{"key":"10930_CR5","doi-asserted-by":"publisher","first-page":"S228","DOI":"10.5489\/cuaj.1203","volume":"3","author":"RS Svatek","year":"2009","unstructured":"Svatek RS, Siefker-Radtke A, Dinney CP. Management of metastatic urothelial cancer: the role of surgery as an adjunct to chemotherapy. Can Urol Assoc J. 2009;3:S228\u201331.","journal-title":"Can Urol Assoc J"},{"key":"10930_CR6","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"H von der Maase","year":"2005","unstructured":"von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602\u20138.","journal-title":"J Clin Oncol"},{"key":"10930_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ejca.2005.08.032","volume":"42","author":"CN Sternberg","year":"2006","unstructured":"Sternberg CN, de Mulder P, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006;42:50\u20134.","journal-title":"Eur J Cancer"},{"key":"10930_CR8","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1200\/JCO.1997.15.7.2564","volume":"15","author":"SB Saxman","year":"1997","unstructured":"Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997;15:2564\u20139.","journal-title":"J Clin Oncol"},{"key":"10930_CR9","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1200\/JCO.2011.38.6979","volume":"30","author":"J Bellmunt","year":"2012","unstructured":"Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G, et al. Randomized phase III study comparing paclitaxel\/cisplatin\/gemcitabine and gemcitabine\/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC intergroup study 30987. J Clin Oncol. 2012;30:1107\u201313.","journal-title":"J Clin Oncol"},{"key":"10930_CR10","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1634\/theoncologist.2018-0084","volume":"24","author":"DL Suzman","year":"2019","unstructured":"Suzman DL, Agrawal S, Ning YM, Maher VE, Fernandes LL, Karuri S, et al. FDA approval summary: atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy. Oncologist. 2019;24:563\u20139.","journal-title":"Oncologist"},{"key":"10930_CR11","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.juro.2015.06.115","volume":"195","author":"C Oing","year":"2016","unstructured":"Oing C, Rink M, Oechsle K, Seidel C, von Amsberg G, Bokemeyer C. Second line chemotherapy for advanced and metastatic urothelial carcinoma: vinflunine and beyond\u2014a comprehensive review of the current literature. J Urol. 2016;195:254\u201363.","journal-title":"J Urol"},{"key":"10930_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/annonc\/mdv509","volume":"27","author":"D Raggi","year":"2016","unstructured":"Raggi D, Miceli R, Sonpavde G, Giannatempo P, Mariani L, Galsky MD, et al. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol. 2016;27:49\u201361.","journal-title":"Ann Oncol"},{"key":"10930_CR13","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1200\/JCO.2008.20.5534","volume":"27","author":"J Bellmunt","year":"2009","unstructured":"Bellmunt J, Th\u00e9odore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27:4454\u201361.","journal-title":"J Clin Oncol"},{"key":"10930_CR14","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1093\/annonc\/mdt007","volume":"24","author":"J Bellmunt","year":"2013","unstructured":"Bellmunt J, Fougeray R, Rosenberg JE, von der Maase H, Schutz FA, Salhi Y, et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol. 2013;24:1466\u201372.","journal-title":"Ann Oncol"},{"key":"10930_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3390\/cancers13010131","volume":"13","author":"A Lopez-Beltran","year":"2021","unstructured":"Lopez-Beltran A, Cimadamore A, Blanca A, Massari F, Vau N, Scarpelli M, et al. Immune checkpoint inhibitors for the treatment of bladder cancer. Cancers (Basel). 2021;13:131.","journal-title":"Cancers (Basel)"},{"key":"10930_CR16","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376:1015\u201326.","journal-title":"N Engl J Med"},{"key":"10930_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10147-018-1260-0","volume":"23","author":"T Yuasa","year":"2018","unstructured":"Yuasa T, Urakami S, Yonese J. Recent advances in medical therapy for metastatic urothelial cancer. Int J Clin Oncol. 2018;23:599\u2013607.","journal-title":"Int J Clin Oncol"},{"key":"10930_CR18","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1002\/cam4.3863","volume":"10","author":"K Ito","year":"2021","unstructured":"Ito K, Kobayashi T, Kojima T, Hikami K, Yamada T, Ogawa K, et al. Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: analysis of a Japanese nationwide cohort. Cancer Med. 2021;10:3188\u201396.","journal-title":"Cancer Med"},{"key":"10930_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10147-019-01545-4","volume":"25","author":"H Nishiyama","year":"2020","unstructured":"Nishiyama H, Yamamoto Y, Sassa N, Nishimura K, Fujimoto K, Fukasawa S, et al. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial. Int J Clin Oncol. 2020;25:165\u201374.","journal-title":"Int J Clin Oncol"},{"key":"10930_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15439","author":"N Yamamoto","year":"2022","unstructured":"Yamamoto N, Kamitani T, Kanda K, Ito Y, Hamada M, Ozaki M, et al. Real-world outcomes of pembrolizumab monotherapy in non-small cell lung cancer in Japan: a post-marketing surveillance. Cancer Sci. 2022;113:3110\u20139.","journal-title":"Cancer Sci (in press)"},{"key":"10930_CR21","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/1346-8138.16518","volume":"49","author":"N Yamazaki","year":"2022","unstructured":"Yamazaki N, Shimizu A, Ozaki M, Hamada M, Takeuchi N, Ito Y, et al. Real-world safety and effectiveness of pembrolizumab in Japanese patients with radically unresectable melanoma: an all-case postmarketing surveillance in Japan. J Dermatol. 2022;49:1096\u2013105.","journal-title":"J Dermatol"},{"key":"10930_CR22","unstructured":"MSD K.K. Risk management plan for Keytruda\u24c7 intravenous infusion 100 mg (in Japanese). https:\/\/www.pmda.go.jp\/RMP\/www\/170050\/bb2e759c-bd7f-4577-b27c-342a2524de1d\/170050_4291435A1029_025RMP.pdf. Accessed 24 Mar 2023."},{"key":"10930_CR23","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.3389\/fphar.2018.01430","volume":"9","author":"K Ma","year":"2018","unstructured":"Ma K, Lu Y, Jiang S, Tang J, Li X, Zhang Y. The relative risk and incidence of immune checkpoint inhibitors related pneumonitis in patients with advanced cancer: a meta-analysis. Front Pharmacol. 2018;9:1430.","journal-title":"Front Pharmacol"},{"key":"10930_CR24","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","volume":"28","author":"J Bellmunt","year":"2010","unstructured":"Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010;28:1850\u20135.","journal-title":"J Clin Oncol"},{"key":"10930_CR25","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/cas.14762","volume":"112","author":"T Kobayashi","year":"2021","unstructured":"Kobayashi T, Ito K, Kojima T, Kato M, Kanda S, Hatakeyama S, et al. Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab. Cancer Sci. 2021;112:760\u201373.","journal-title":"Cancer Sci"},{"key":"10930_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001279","volume":"33","author":"S Fukata","year":"2022","unstructured":"Fukata S, Mizutani K, Yamamoto S, Kuno T, Fukuhara H, Ashida S, et al. Sarcopenia and the rate of change of the neutrophil\/lymphocyte ratio as predictors of pembrolizumab efficacy in advanced urothelial carcinoma. Anticancer Drugs. 2022;33:459\u201366.","journal-title":"Anticancer Drugs"},{"issue":"344","key":"10930_CR27","first-page":"e11","volume":"40","author":"T Uchimoto","year":"2022","unstructured":"Uchimoto T, Nakamura K, Komura K, Fukuokaya W, Yano Y, Nishimura K, et al. Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma. Urol Oncol. 2022;40:344.e11\u20137.","journal-title":"Urol Oncol"},{"key":"10930_CR28","doi-asserted-by":"publisher","first-page":"e003965","DOI":"10.1136\/jitc-2021-003965","volume":"10","author":"T Kawai","year":"2022","unstructured":"Kawai T, Taguchi S, Nakagawa T, Kamei J, Nakamura Y, Obinata D, et al. Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis. J Immunother Cancer. 2022;10:e003965.","journal-title":"J Immunother Cancer"},{"key":"10930_CR29","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2147\/CMAR.S348899","volume":"14","author":"M Miyake","year":"2022","unstructured":"Miyake M, Nishimura N, Shimizu T, Ohnishi M, Kuwada M, Itami Y, et al. Significant improvement of prognosis after the advent of\u00a0immune checkpoint inhibitors in patients with advanced, unresectable, or metastatic urothelial carcinoma: a propensity score matching and inverse probability of treatment weighting analysis on real-world data. Cancer Manag Res. 2022;14:623\u201335.","journal-title":"Cancer Manag Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-10930-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-023-10930-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-10930-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T09:04:00Z","timestamp":1687251840000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-023-10930-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["10930"],"URL":"https:\/\/doi.org\/10.1186\/s12885-023-10930-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,20]]},"assertion":[{"value":"10 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This post-marketing surveillance conformed to the provisions of the Declaration of Helsinki and was conducted based on the Good Post-Marketing Study Practice authorized by the Ministry of Health, Labour and Welfare of Japan (Ordinance No. 171, 2004). The ordinance exempts the requirement of ethical review and patients\u2019 informed consent in post-marketing surveillance.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HN has received all support for the present manuscript from MSD; grants or contracts from Ono Pharmaceutical, Astellas Pharma, Bayer, and Chugai Pharmaceutical through his\u00a0own institution; consulting fees from Ono Pharmaceutical, Janssen Pharmaceutical, AstraZeneca, and MSD; and payment or honoraria from Olympus, Astellas Pharma, Merck Biopharma, and MSD. YT was an employee of MSD at the time of the study. MH is an employee of MSD; and holds stock or stock options in Merck & Co., and Organon & Co. MO is an employee of MSD and holds stock or stock options in Merck & Co. TM is an employee of MSD and holds stock or stock options in Merck and GlaxoSmithKline. YI is an employee of MSD; and holds stock or stock options in Merck & Co., and Bayer AG. SM is an employee of MSD and holds stock or stock options in Merck. NY has received grants or contracts from MSD, AstraZeneca, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical., Pfizer, Amgen, Janssen Pharmaceutical, Toppan Printing, Terumo, and Boehringer-Ingelheim through his\u00a0own institution; consulting fees from AstraZeneca, Daiichi Sankyo, Taiho Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Eli Lilly Japan, Boehringer-Ingelheim, Novartis, Bristol-Myers Squibb, Nippon Kayaku, Life Technologies Japan, Amgen, Guardant Health Japan, and Janssen Pharmaceutical; honoraria from MSD, AstraZeneca, Ono Pharmaceutical, Thermo Fisher Scientific, Daiichi Sankyo, Taiho Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Eli Lilly Japan, Boehringer-Ingelheim, Novartis, Pfizer, Bristol-Myers Squibb, Nippon Kayaku, GlaxoSmithKline, Sanofi, Hisamitsu Pharmaceutical, and Merck Biopharma; and has participated in a data safety monitoring or advisory board for MSD, AstraZeneca, Ono Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Eli Lilly Japan, Boehringer-Ingelheim, and Pfizer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"565"}}